We are a biopharmaceutical company developing and commercializing therapies for
vascular disorders. Our research and development efforts are focused on
therapies for stroke and other vascular disorders, using our proprietary
microbubble technology to treat vascular occlusions, or blood vessel blockages,
as well as the resulting ischemia, which is tissue damage caused by a reduced
supply of oxygen. Our commercialization efforts are currently focused on our
product approved by the U.S. Food and Drug Administration, or FDA, for the
treatment of acute massive pulmonary embolism, or blood clots in the lungs.
We were organized as an Arizona limited liability company on October 7, 1999,
which was our date of inception for accounting purposes. We were subsequently
converted to an Arizona corporation on January 12, 2000, and then reincorporated
as a Delaware corporation on June 23, 2000. Our principal executive offices are
located at 1635 E. 18th St., Tucson, Arizona 85719, and our telephone number at
that location is (520) 770-1259. Our corporate website address is www.imarx.com.